[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533095":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":42,"collaborators":7,"id":45,"slug":7,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University of Calgary","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Chad Bousman, MPH, PhD","PRINCIPAL_INVESTIGATOR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Weng-Sam Siu, MSPT, MSc","CONTACT","5875739747","sam.siu@ucalgary.ca",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},"Madison Heintz, MSW","psychpgxlab@ucalgary.ca",[22],{"facility":5,"status":23,"city":24,"state":25,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Calgary","Alberta","Canada","CA",{"type":29,"coordinates":30},"Point",[31,32],-114.08529,51.05011,{"lat":32,"lon":31},[35,36,37,40],{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":38,"role":39,"phone":7,"phoneExt":7,"email":7},"Kara Murias, MD, PhD","SUB_INVESTIGATOR",{"name":41,"role":39,"phone":7,"phoneExt":7,"email":7},"Paul Arnold, MD, PhD",{"type":11,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Chad Bousman","Associate Professor","100533095",false,"NCT06221358","Pharmacogenomics of Stimulant Treatment Response","Pharmacogenomics of Stimulant Treatment Response in Children and Adolescents With Attention-Deficit\u002F Hyperactivity Disorder","PGx-STaR","Inclusion Criteria:\n\nPatients will be eligible for participation if all the following are true.\n\n* Aged 6 - 24 years.\n* Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).\n* Primary diagnosis of ADHD (all types).\n* Starting Methylphenidate (excluding immediate release forms) treatment.\n\nExclusion Criteria:\n\nPatients will be excluded from participation if any of the following are true.\n\n* Co-occurring psychotic, bipolar or eating disorders.\n* Significant risk of suicide.\n* An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics\u002FTourette disorders.\n* Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.\n* Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate\u002Fchange these types of therapies during the study\n* History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.","ALL","6 Years","24 Years",{"count":56,"type":57},400,"ESTIMATED","OBSERVATIONAL","The \"Pharmacogenomics of Stimulant Treatment Response\" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit\u002Fhyperactivity disorder (ADHD).",[61],"Attention-Deficit\u002F Hyperactivity Disorder (ADHD)",[63,64,65,66,67,68,69],"Children","Adolescents","ADHD","Pharmacogenetics","Neurology","Psychostimulants","Methylphenidate","2025-11-27",{"date":72,"type":73},"2025-12-05","ACTUAL",{"date":75,"type":73},"2024-04-01",{"date":77,"type":57},"2028-12-31",{"name":5,"class":6},1]